Hugendubel.info - Die B2B Online-Buchhandlung 

Merkliste
Die Merkliste ist leer.
Bitte warten - die Druckansicht der Seite wird vorbereitet.
Der Druckdialog öffnet sich, sobald die Seite vollständig geladen wurde.
Sollte die Druckvorschau unvollständig sein, bitte schliessen und "Erneut drucken" wählen.

Current Immunotherapeutic Strategies in Cancer

BuchKartoniert, Paperback
187 Seiten
Englisch
Springererschienen am20.09.20201st ed. 2020
This book offers a comprehensive review of recent advances in cancer immunotherapy, and explores the value and limitations of the most effective current therapeutic strategies and emerging treatment modalities.mehr
Verfügbare Formate
BuchKartoniert, Paperback
EUR90,94
BuchGebunden
EUR128,39

Produkt

KlappentextThis book offers a comprehensive review of recent advances in cancer immunotherapy, and explores the value and limitations of the most effective current therapeutic strategies and emerging treatment modalities.
Zusammenfassung
Offers a comprehensive review of the most recent developments in cancer immunotherapy

Examines the value and the limitations of newly emerging treatment modalities

Explores advances toward personalized medicine

Written by the world s leading experts in the field
Details
ISBN/GTIN978-3-030-23767-7
ProduktartBuch
EinbandartKartoniert, Paperback
Verlag
Erscheinungsjahr2020
Erscheinungsdatum20.09.2020
Auflage1st ed. 2020
ReiheRecent Results in Cancer Research
Seiten187 Seiten
SpracheEnglisch
IllustrationenV, 187 p.
Artikel-Nr.49027138
Rubriken
GenreMedizin

Inhalt/Kritik

Inhaltsverzeichnis
Current Development of Monoclonal Antibodies in Cancer Therapy.- Clinical Experience with Bispecific T-Cell Engagers.- Advances and challenges of CAR-modified T cells in clinical trials.- Targeting Cancer with Genetically Engineered TCR-T Cells.- Tailored Vaccines Based on Patient´s Cancer Mutanome.- Next-Generation Checkpoint Inhibitors and Immune Agonists.mehr

Autor

Professor Matthias Theobald holds an MD from the University of Ulm, Germany, where he also completed his clinical training in internal medicine, hematology, and oncology. After several years of clinical and experimental research at the Department of Hematology and Oncology, Ulm University Hospital, he moved to La Jolla, CA, to continue basic biomedical research at the Department of Immunology, The Scripps Research Institute. In 1995, he became an experimental group leader and clinical attendee at the Department of Hematology and Oncology, Johannes Gutenberg University (JGU) Medical School, Mainz, Germany. From 2003 to 2006, Dr. Theobald held a José Carreras Leukemia Foundation Chair at JGU, and from 2006 to 2009 he served as a Full Professor of Hematology and Director of the Department of Hematology and Van Creveld Clinic at the University Medical Center Utrecht, the Netherlands. Since 2009, Dr. Theobald has been a Professor of Hematology and Oncology and Director of the Department of Hematology, Oncology, and Pneumology at the JGU Medical Center Mainz, Germany. He has served as the Chairman of the University Cancer Center Mainz since 2011, was Associate Editor of The Hematology Journal and serves on various other editorial boards. He is an expert in clinical leukemia research, immunotherapy of malignant diseases, and in experimental tumor and stem cell transplantation immunology. His laboratory has been instrumental in the development of TCR gene therapy as a novel tool in tackling malignant disease.
Weitere Artikel von
Herausgegeben:Theobald, Matthias